<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031546</url>
  </required_header>
  <id_info>
    <org_study_id>CR845-500301</org_study_id>
    <nct_id>NCT05031546</nct_id>
  </id_info>
  <brief_title>Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin</brief_title>
  <official_title>Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cara Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cara Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      This is an intermediate-size patient population expanded access protocol for the use of&#xD;
      intravenous (IV) difelikefalin for the treatment of moderate-to-severe pruritus associated&#xD;
      with chronic kidney disease in adult patients undergoing hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visits during the expanded access program will consist of a Baseline Visit to confirm&#xD;
      eligibility and an End of Treatment visit. Patients will receive IV difelikefalin at a dose&#xD;
      of 0.5 mcg/kg after each dialysis session, generally 3 times per week. The End of Treatment&#xD;
      visit will be defined as the first dialysis visit following the last dose of IV difelikefalin&#xD;
      under the intermediate-size patient population expanded access protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Uremic Pruritus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Difelikefalin</intervention_name>
    <description>IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 18 years old;&#xD;
&#xD;
          -  Has end-stage renal disease (ESRD) and is currently receiving in-center hemodialysis;&#xD;
&#xD;
          -  Has moderate-to-severe pruritus attributed to ESRD which is significantly impacting&#xD;
             the patient's quality of life;&#xD;
&#xD;
          -  Has no comparable or satisfactory alternative therapy for the treatment of&#xD;
             moderate-to-severe pruritus, as determined by the sponsor-investigator.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Has severe hepatic impairment (Child-Pugh class C), as the influence of severe hepatic&#xD;
             impairment on the pharmacokinetics of difelikefalin has not been evaluated;&#xD;
&#xD;
          -  Is pregnant or nursing;&#xD;
&#xD;
          -  Has been exposed to any other investigational medication in the past 60 days;&#xD;
&#xD;
          -  Present any other reason which may lead to an unfavorable risk-benefit ratio for&#xD;
             treatment with difelikefalin, as determined by the sponsor-investigator;&#xD;
&#xD;
          -  Has a known or suspected allergy to difelikefalin or any component of the&#xD;
             investigational product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Frédérique Menzaghi, PhD</last_name>
    <phone>203-406-3700</phone>
    <email>clinicaltrials.gov@caratherapeutics.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Uremic Pruritus</keyword>
  <keyword>Dialysis</keyword>
  <keyword>CR845</keyword>
  <keyword>Difelikefalin</keyword>
  <keyword>Chronic Itch</keyword>
  <keyword>CKD</keyword>
  <keyword>CKD-associated pruritus</keyword>
  <keyword>CKD-aP</keyword>
  <keyword>ESRD (end stage renal disease)</keyword>
  <keyword>Itch</keyword>
  <keyword>Itching</keyword>
  <keyword>KALM</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Kidney failure, chronic</keyword>
  <keyword>Kidney dysfunction</keyword>
  <keyword>Generalized pruritus</keyword>
  <keyword>Expanded access</keyword>
  <keyword>Compassionate use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

